Search
Now showing items 91-100 of 170
Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)
(2020-12)
Meeting abstract P0196 from MSVirtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13, 2020
Identifying Gaps in Knowledge, Skill and Confidence Among MS Specialists to Facilitate Appropriate Evolutions in MS Care
(2020-04-14)
Meeting abstract 444 from Annual Meeting of the American-Academy-of-Neurology, Toronto, CANADA APR 25-MAY 01, 2020
A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis
(2020-04-14)
Meeting Abstract 1487 from 72nd Annual Meeting of the American Academy of Neurology
Toronto 25 April–1 May 2020
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
(Lippincott, Williams & Wilkins, 2020-11)
Objective: To evaluate the use of CSF neurofilament light chain (NfL) measurements in clinical practice as well as their effect on treatment strategies and outcomes in multiple sclerosis (MS) patients. Methods: This was ...
Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis.
(2020-05-13)
OBJECTIVE: Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape for people with relapsing-remitting multiple sclerosis (pwRRMS). A challenge for services is how to support DMT decisions with ...
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
(2020-06-08)
OBJECTIVE: Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion ...